Bedford Laboratories, a division of Ben Venue Laboratories, Inc announced FDA approval to begin shipping ceftriaxone for Injection USP. This product is AP rated and is equivalent to Rocephin by Roche. ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to treat several types of infections caused by susceptible bacteria.

"In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to begin offering this product which represents Bedford's entry into the cephalosporin market. This continues to demonstrate our commitment to providing a broad based portfolio of products," said David Gaugh, vice president and general manager of Bedford Laboratories.

Bedford Laboratories will supply ceftriaxone for Injection USP as a sterile crystalline powder in glass vials in the following presentations: Single-dose vials containing either 250mg, 500mg, 1g, or 2g equivalent of ceftriaxone packaged in cartons containing 10 vials and a pharmacy bulk vial containing the equivalent of 10g ceftriaxone packaged in cartons containing 1 vial.